Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
研究概览
地位
条件
详细说明
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.
Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.
A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.
研究类型
联系人和位置
学习地点
-
-
-
Chongqing、中国
- The First Affiliated Hospital of Chongqing Medical University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Adult aged >=18years old;
- Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
- Diagnosed with primary hypertension.
- Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.
Exclusion Criteria:
- Near-death state (expected survival time less than 24 hours);
- Malignant tumor;
- Pregnancy or puerperium women;
- ACEI contraindication
- Patients who refused to participant.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
|
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Occupancy rate in the intensive care unit (ICU)
大体时间:up to 28 days
|
The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
|
up to 28 days
|
Mechanical Ventilation
大体时间:up to 28 days
|
The number of patients requiring mechanical ventilation.
|
up to 28 days
|
Death
大体时间:up to 28 days
|
The number of patients who died of 2019-nCoV infection.
|
up to 28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
All cause mortality
大体时间:up to 28 days
|
The number of died 2019-nCoV infected patients from any cause.
|
up to 28 days
|
Time from onset of symptoms to main outcome and its components
大体时间:up to 28 days
|
Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
|
up to 28 days
|
Time to Clinical Recovery
大体时间:up to 28 days
|
Time to Clinical Recovery
|
up to 28 days
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
2019新型冠状病毒的临床试验
-
Leidos Life SciencesUnited States Department of Defense主动,不招人新冠肺炎 | 新冠肺炎 | 2019冠状病毒病 | SARS-CoV-2 感染 | SARS-CoV-2 急性呼吸道疾病 | 2019冠状病毒病大流行 | COVID-19 病毒感染 | COVID-19 病毒病 | 2019新型冠状病毒病 | 2019新型冠状病毒感染 | 2019-nCoV 疾病 | 2019-nCoV 感染美国
-
Leidos Life SciencesUnited States Department of Defense撤销新冠肺炎 | 新冠肺炎 | 2019冠状病毒病 | SARS-CoV-2 感染 | SARS-CoV-2 急性呼吸道疾病 | 2019冠状病毒病大流行 | COVID-19 病毒感染 | COVID-19 病毒病 | 2019新型冠状病毒病 | 2019新型冠状病毒感染 | 2019-nCoV 疾病 | 2019-nCoV 感染
-
Leidos Life SciencesUnited States Department of Defense终止新冠肺炎 | 新冠肺炎 | 2019冠状病毒病 | SARS-CoV2 感染 | SARS-CoV-2 急性呼吸道疾病 | 2019冠状病毒病大流行 | COVID-19 病毒感染 | COVID-19 病毒病 | 2019新型冠状病毒病 | 2019新型冠状病毒感染 | 2019-nCoV 疾病 | 2019-nCoV 感染美国
-
Beijing Children's HospitalThe First Affiliated Hospital of Anhui Medical University; Shengjing Hospital; China-Japan Friendship... 和其他合作者未知
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical Consultants LLC; R....完全的2019冠状病毒病 | SARS-CoV-2 感染 | 2019冠状病毒病大流行 | COVID-19 病毒感染 | 冠状病毒病 19 | COVID-19 病毒病 | 2019新型冠状病毒病 | 2019新型冠状病毒感染 | 2019-nCoV 疾病美国
-
Institut National de la Santé Et de la Recherche...暂停
-
Jeffrey BluestoneNational Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)终止